Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Arimoclomol,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Treatment for Niemann-Pick Disease, Type C
Details : Miplyffa (Arimoclomol) is indicated for use in combination with miglustat for the treatment of Niemann-Pick disease type C in adult and pediatric patients 2 years of age and older.
Brand Name : Miplyffa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 20, 2024
Lead Product(s) : Arimoclomol,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Cantor
Deal Size : Undisclosed
Deal Type : Public Offering
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
Details : The net proceeds from this offering will used to support the pre-commercial launch activities for BRX-345 (arimoclomol) for the treatment of Niemann-Pick Disease Type C.
Brand Name : BRX-345
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 08, 2024
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Cantor
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Advisory Committee Supports Arimoclomol as Effective for Niemann-Pick Disease Type C
Details : BRX-345 (arimoclomol) is a first in class oral HSF1 activator being investigated for Niemann-Pick disease type C. The FDA has accepted the resubmitted NDA and set a PDUFA date of September 21, 2024.
Brand Name : BRX-345
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2024
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zevra Announces FDA Advisory Committee Meeting for Arimoclomol in Niemann-Pick Disease
Details : BRX-345 (arimoclomol) is a first in class oral HSF1 activator being investigated for Niemann-Pick disease type C. The FDA has accepted the resubmitted NDA and set a PDUFA date of September 21, 2024.
Brand Name : BRX-345
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Serdexmethylphenidate
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zevra Announces Positive Phase 2 Results of KP1077 for Hypersomnia at SLEEP 2024
Details : KP1077 (serdexmethylphenidate) is a prodrug of d-methylphenidate, which acts as dopamine & norepinephrine transporter antagonists. It is being evaluated for the treatment of idiopathic hypersomnia.
Brand Name : KP1077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 03, 2024
Lead Product(s) : Serdexmethylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Perceptive Advisors
Deal Size : Undisclosed
Deal Type : Financing
Zevra Refinances Debt with Up to $100M in Committed Capital Under New Credit Facility
Details : The net proceeds will be used for launching Olpruva, a new formulation of sodium phenylbutyrate approved as an oral suspension by the FDA, to treat patients with urea cycle disorders.
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 10, 2024
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Perceptive Advisors
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Serdexmethylphenidate
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zevra Announces Top-Line Data From Phase 2 Trial Of KP1077 For Idiopathic Hypersomnia
Details : KP1077 (serdexmethylphenidate) is a prodrug of d-methylphenidate, which acts as dopamine & norepinephrine transporter antagonists. It is being evaluated for the treatment of idiopathic hypersomnia.
Brand Name : KP1077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : Serdexmethylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zevra Therapeutics Provides FDA Update on PDUFA Action Date for Arimoclomol Treatment
Details : BRX-345 (arimoclomol) is a first in class investigational HSF1 activator, which is being evaluated in phase 2/3 clinical trials for the treatment of Niemann-Pick disease type C.
Brand Name : BRX-345
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2024
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zevra Therapeutics Receives FDA Acceptance of NDA Resubmission for Arimoclomol Treatment
Details : Arimoclomol is a first in class investigational HSF1 activator, which is under phase 2/3 clinical development for the treatment of Niemann-Pick disease type C.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Arimoclomol is a first in class investigational HSF1 activator, which is under phase 2/3 clinical development for the treatment of Niemann-Pick disease type C.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 27, 2023
Lead Product(s) : Arimoclomol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?